91 related articles for article (PubMed ID: 18990485)
21. Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model.
Dean NR; Knowles JA; Helman EE; Aldridge JC; Carroll WR; Magnuson JS; Clemons L; Ziober B; Rosenthal EL
Anticancer Drugs; 2010 Oct; 21(9):861-7. PubMed ID: 20700044
[TBL] [Abstract][Full Text] [Related]
22. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
23. Marked inhibition of growth and invasive parameters of head and neck squamous carcinoma FaDu by a nutrient mixture.
Roomi MW; Roomi NW; Kalinovsky T; Rath M; Niedzwiecki A
Integr Cancer Ther; 2009 Jun; 8(2):168-76. PubMed ID: 19679626
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Riedel F; Götte K; Hörmann K; Grandis JR
Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
[TBL] [Abstract][Full Text] [Related]
25. The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck.
Teknos TN; Islam M; Arenberg DA; Pan Q; Carskadon SL; Abarbanell AM; Marcus B; Paul S; Vandenberg CD; Carron M; Nor JE; Merajver SD
Arch Otolaryngol Head Neck Surg; 2005 Mar; 131(3):204-11. PubMed ID: 15781759
[TBL] [Abstract][Full Text] [Related]
26. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
27. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts.
Seshadri M; Merzianu M; Tang H; Rigual NR; Sullivan M; Loree TR; Popat SR; Repasky EA; Hylander BL
Cancer Biol Ther; 2009 Dec; 8(23):2275-83. PubMed ID: 19829072
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.
Selvakumaran M; Yao KS; Feldman MD; O'Dwyer PJ
Biochem Pharmacol; 2008 Feb; 75(3):627-38. PubMed ID: 18178171
[TBL] [Abstract][Full Text] [Related]
31. Effects of hyperbaric oxygen exposure on experimental head and neck tumor growth, oxygenation, and vasculature.
Shi Y; Lee CS; Wu J; Koch CJ; Thom SR; Maity A; Bernhard EJ
Head Neck; 2005 May; 27(5):362-9. PubMed ID: 15818558
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
[TBL] [Abstract][Full Text] [Related]
33. Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts.
Withrow KP; Newman JR; Skipper JB; Gleysteen JP; Magnuson JS; Zinn K; Rosenthal EL
Technol Cancer Res Treat; 2008 Feb; 7(1):61-6. PubMed ID: 18198926
[TBL] [Abstract][Full Text] [Related]
34. EMMPRIN modulates migration and deposition of TN-C in oral squamous carcinoma.
Dang D; Atakilit A; Ramos DM
Anticancer Res; 2008; 28(4B):2049-54. PubMed ID: 18751374
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
Cheng J; Ekberg T; Engström M; Nestor M; Jensen HJ; Tolmachev V; Anniko M
Laryngoscope; 2007 Jun; 117(6):1013-8. PubMed ID: 17440426
[TBL] [Abstract][Full Text] [Related]
36. Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.
Cheng MF; Tzao C; Tsai WC; Lee WH; Chen A; Chiang H; Sheu LF; Jin JS
Dis Esophagus; 2006; 19(6):482-6. PubMed ID: 17069593
[TBL] [Abstract][Full Text] [Related]
37. Insulin-like growth factor binding protein-5 (IGFBP-5) suppresses the tumourigenesis of head and neck squamous cell carcinoma.
Hung PS; Kao SY; Shih YH; Chiou SH; Liu CJ; Chang KW; Lin SC
J Pathol; 2008 Feb; 214(3):368-76. PubMed ID: 18085517
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy for head and neck cancer: signaling pathways and clinical studies.
Li Q; Tie Y; Alu A; Ma X; Shi H
Signal Transduct Target Ther; 2023 Jan; 8(1):31. PubMed ID: 36646686
[TBL] [Abstract][Full Text] [Related]
39. CD147 promotes the proliferation, invasiveness, migration and angiogenesis of human lung carcinoma cells.
Yang S; Qi F; Tang C; Wang H; Qin H; Li X; Li J; Wang W; Zhao C; Gao H
Oncol Lett; 2017 Feb; 13(2):898-904. PubMed ID: 28356976
[TBL] [Abstract][Full Text] [Related]
40. Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models.
Triana-Baltzer G; Pavlicek A; Goulart A; Huang H; Pirie-Shepherd S; Levin N
PLoS One; 2013; 8(11):e80132. PubMed ID: 24244628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
